stockrowLatest quarter
Veradermics reported adjusted earnings per share of −$0.58 for the quarter ended June 30, 2026, matching the consensus estimate of −$0.58. Its diluted loss per share was −$0.58, compared with −$24.19 a year earlier. Free cash flow was −$14.5 million, compared with −$15.6 million in the prior-year quarter.
Veradermics is developing treatments for aesthetic and dermatological conditions and has no products approved for commercial sale. Its lead candidate, VDPHL01, is an oral, non-hormonal treatment being studied for pattern hair loss. The company says it currently generates no revenue from product sales and has financed operations primarily through preferred stock sales and proceeds from its initial public offering.
| Q2 FY2026 | Q2 FY2025 | Change | |
|---|---|---|---|
| Diluted EPS | −$0.58 | −$24.19 | — |
| Free cash flow | −$14.5 million | −$15.6 million | — |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | −$0.58 | −$0.58 | In line |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
No earnings call for the quarter is available, so management’s commentary and analysts’ questions cannot be reported.
Guidance
Veradermics said its liquidity fully funds upcoming regulatory submissions and preparations for a commercial launch. Management’s guidance is not available, so changes to its outlook cannot be established.